## Laura Torrens

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3980371/publications.pdf

Version: 2024-02-01

| 7        | 522            | 7            | 7              |
|----------|----------------|--------------|----------------|
| papers   | citations      | h-index      | g-index        |
| 7        | 7              | 7            | 675            |
| all docs | docs citations | times ranked | citing authors |

| # | Article   | IF   | CITATION |
|---|---|------|----------|
| 1 | Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity. Journal of Hepatology, 2017, 66, 952-961.                                     | 3.7  | 120      |
| 2 | Immunomodulatory Effects of Lenvatinib Plus Anti–Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma. Hepatology, 2021, 74, 2652-2669. | 7.3  | 95       |
| 3 | Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification. Gut, 2023, 72, 129-140.   | 12.1 | 90       |
| 4 | Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications. Journal of Hepatology, 2020, 73, 328-341.  | 3.7  | 82       |
| 5 | Liver Injury Increases the Incidence of HCC following AAV Gene Therapy in Mice. Molecular Therapy, 2021, 29, 680-690.   | 8.2  | 61       |
| 6 | Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma. Clinical Cancer Research, 2022, 28, 2449-2460.                          | 7.0  | 39       |
| 7 | Copy-Number Alteration Burden Differentially Impacts Immune Profiles and Molecular Features of Hepatocellular Carcinoma. Clinical Cancer Research, 2020, 26, 6350-6361.                     | 7.0  | 35       |